UY34955A - 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos - Google Patents
4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenosInfo
- Publication number
- UY34955A UY34955A UY0001034955A UY34955A UY34955A UY 34955 A UY34955 A UY 34955A UY 0001034955 A UY0001034955 A UY 0001034955A UY 34955 A UY34955 A UY 34955A UY 34955 A UY34955 A UY 34955A
- Authority
- UY
- Uruguay
- Prior art keywords
- methyl
- naftalenos
- ciclopenta
- pentaaza
- diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- HZYVDROSDKAHQE-UHFFFAOYSA-N CC1=NC2=CC=CN=C2N2C1=NN=C2 Chemical class CC1=NC2=CC=CN=C2N2C1=NN=C2 HZYVDROSDKAHQE-UHFFFAOYSA-N 0.000 abstract 1
- 101001098814 Dictyostelium discoideum 3',5'-cyclic-nucleotide phosphodiesterase regA Proteins 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12178713 | 2012-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY34955A true UY34955A (es) | 2014-01-31 |
Family
ID=48906250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001034955A UY34955A (es) | 2012-07-31 | 2013-07-31 | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20140045856A1 (enExample) |
| EP (1) | EP2882749B1 (enExample) |
| JP (1) | JP6356671B2 (enExample) |
| KR (1) | KR20150037950A (enExample) |
| CN (1) | CN104428302B (enExample) |
| AP (1) | AP2015008202A0 (enExample) |
| AR (1) | AR091939A1 (enExample) |
| AU (1) | AU2013298621B2 (enExample) |
| BR (1) | BR112015002118A2 (enExample) |
| CA (1) | CA2880447A1 (enExample) |
| CL (1) | CL2015000096A1 (enExample) |
| CO (1) | CO7310531A2 (enExample) |
| EA (1) | EA028958B1 (enExample) |
| EC (1) | ECSP15006871A (enExample) |
| GE (1) | GEP201706707B (enExample) |
| IL (1) | IL236494A0 (enExample) |
| MA (1) | MA37798B1 (enExample) |
| MX (1) | MX2015000965A (enExample) |
| NZ (1) | NZ703797A (enExample) |
| PE (1) | PE20150706A1 (enExample) |
| PH (1) | PH12015500211B1 (enExample) |
| SG (1) | SG11201500772VA (enExample) |
| TN (1) | TN2015000022A1 (enExample) |
| TW (1) | TW201418255A (enExample) |
| UA (1) | UA115561C2 (enExample) |
| UY (1) | UY34955A (enExample) |
| WO (1) | WO2014019979A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| US9056863B2 (en) * | 2011-09-09 | 2015-06-16 | H. Lundbeck A/S | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof |
| US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
| EP3285581B1 (en) | 2015-03-26 | 2021-08-11 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
| EP3291817B1 (en) | 2015-05-05 | 2019-10-02 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as pde2 inhibitors |
| WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
| CN107614501B (zh) * | 2015-05-20 | 2020-01-14 | 广东众生睿创生物科技有限公司 | 羟基嘌呤类化合物及其应用 |
| WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| WO2016192083A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| US10647727B2 (en) | 2015-06-25 | 2020-05-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors |
| WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
| EP3156405A1 (en) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| CA3054674A1 (en) | 2016-04-04 | 2017-12-10 | Sinopia Biosciences, Inc. | Treating extrapyramidal syndrome using trapidil |
| AR112457A1 (es) * | 2017-08-02 | 2019-10-30 | Lilly Co Eli | Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona |
| US11419874B2 (en) | 2017-11-23 | 2022-08-23 | Oslo University Hospital Hf | Treatment of tachycardia |
| IL296788A (en) | 2020-03-26 | 2022-11-01 | Sinopia Biosciences Inc | Isotopically labeled trepidil histories |
| CN115960101B (zh) * | 2022-12-30 | 2024-10-18 | 海南大学 | 7-氧代-4,5,6,7-四氢吡唑并吡啶酰胺类化合物及其制备方法和应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000319277A (ja) * | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
| JP2000319278A (ja) * | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
| DE10108752A1 (de) | 2001-02-23 | 2002-09-05 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| EP1613629A1 (en) | 2003-03-27 | 2006-01-11 | Pfizer Products Inc. | Substituted 4-amino 1,2,4 triazolo 4,3-a quinoxalines |
| WO2005041957A1 (en) | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
| CA2549510A1 (en) | 2003-12-16 | 2005-07-07 | Pfizer Products Inc. | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors |
| EP1548011A1 (en) | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
| FR2865331A1 (fr) | 2004-01-21 | 2005-07-22 | France Telecom | Procede de connexion d'un reseau domestique a un serveur cops distant et dispositif associe |
| FR2870539B1 (fr) | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | Nouvelles methodes et medicaments |
| WO2006024640A2 (en) | 2004-09-02 | 2006-03-09 | Altana Pharma Ag | Triazolophthalazines |
| JP5130053B2 (ja) | 2005-01-05 | 2013-01-30 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | トリアゾロフタラジン |
| MX2007008137A (es) | 2005-01-05 | 2007-07-19 | Altana Pharma Ag | Triazoloftalazinas como inhibidores de pde2. |
| BRPI0502411A (pt) | 2005-03-31 | 2006-11-28 | Univ Minas Gerais | processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados |
| CA2636043A1 (en) | 2006-01-23 | 2007-08-02 | Amira Pharmaceuticals, Inc. | Tricyclic inhibitors of 5-lipoxygenase |
| WO2007121319A2 (en) | 2006-04-14 | 2007-10-25 | University Of California | Compostions and methods for determining and predicting treatment responses for depression and anxiety |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| DE102006048693A1 (de) | 2006-10-14 | 2008-04-17 | Bayer Healthcare Ag | Inhibition der PDE2A |
| WO2008072779A1 (ja) * | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | キノキサリン誘導体 |
| US20090143361A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| JP2012502067A (ja) | 2008-09-10 | 2012-01-26 | カリプシス・インコーポレーテッド | 疾患の治療のためのヒスタミン受容体の複素環阻害剤 |
| WO2010047956A1 (en) | 2008-10-08 | 2010-04-29 | Bristol-Myers Squibb Company | Azolopyrrolone melanin concentrating hormone receptor-1 antagonists |
| WO2010054253A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Triazine derivatives as inhibitors of phosphodiesterases |
| EP2406250B1 (en) * | 2009-03-11 | 2015-08-12 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| EP2266985A1 (en) * | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Tricyclic Pyrimidine Derivatives as Wnt antagonists |
| JP6106603B2 (ja) * | 2011-01-11 | 2017-04-05 | スノビオン プハルマセウトイカルス インコーポレイテッド | ヘテロアリール化合物及びその使用方法 |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| JP6115962B2 (ja) | 2011-06-27 | 2017-04-19 | ヤンセン ファーマシューティカ エヌ．ベー． | １−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］キノキサリン誘導体 |
| WO2013034758A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Substituted triazolopyrazines and uses thereof |
| US9056863B2 (en) | 2011-09-09 | 2015-06-16 | H. Lundbeck A/S | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| WO2014001314A1 (en) | 2012-06-26 | 2014-01-03 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
-
2013
- 2013-07-18 US US13/945,008 patent/US20140045856A1/en not_active Abandoned
- 2013-07-26 US US13/951,531 patent/US9085584B2/en active Active
- 2013-07-29 PE PE2015000102A patent/PE20150706A1/es not_active Application Discontinuation
- 2013-07-29 MA MA37798A patent/MA37798B1/fr unknown
- 2013-07-29 WO PCT/EP2013/065894 patent/WO2014019979A1/en not_active Ceased
- 2013-07-29 BR BR112015002118A patent/BR112015002118A2/pt not_active IP Right Cessation
- 2013-07-29 AU AU2013298621A patent/AU2013298621B2/en not_active Ceased
- 2013-07-29 SG SG11201500772VA patent/SG11201500772VA/en unknown
- 2013-07-29 MX MX2015000965A patent/MX2015000965A/es unknown
- 2013-07-29 EA EA201500182A patent/EA028958B1/ru not_active IP Right Cessation
- 2013-07-29 CA CA2880447A patent/CA2880447A1/en not_active Abandoned
- 2013-07-29 KR KR20157002607A patent/KR20150037950A/ko not_active Withdrawn
- 2013-07-29 EP EP13742632.6A patent/EP2882749B1/en active Active
- 2013-07-29 NZ NZ703797A patent/NZ703797A/en not_active IP Right Cessation
- 2013-07-29 JP JP2015524750A patent/JP6356671B2/ja active Active
- 2013-07-29 CN CN201380037349.6A patent/CN104428302B/zh not_active Expired - Fee Related
- 2013-07-29 UA UAA201501673A patent/UA115561C2/uk unknown
- 2013-07-29 AP AP2015008202A patent/AP2015008202A0/xx unknown
- 2013-07-29 GE GEAP201313748A patent/GEP201706707B/en unknown
- 2013-07-30 TW TW102127314A patent/TW201418255A/zh unknown
- 2013-07-30 AR ARP130102708A patent/AR091939A1/es unknown
- 2013-07-31 UY UY0001034955A patent/UY34955A/es unknown
-
2014
- 2014-12-28 IL IL236494A patent/IL236494A0/en unknown
-
2015
- 2015-01-14 CL CL2015000096A patent/CL2015000096A1/es unknown
- 2015-01-16 TN TNP2015000022A patent/TN2015000022A1/fr unknown
- 2015-01-29 CO CO15018184A patent/CO7310531A2/es unknown
- 2015-01-30 PH PH12015500211A patent/PH12015500211B1/en unknown
- 2015-02-25 EC ECIEPI20156871A patent/ECSP15006871A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP15006871A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| CL2017002650A1 (es) | Compuestos novedosos | |
| CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
| NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
| CU24187B1 (es) | Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| CR20140161A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| GT201500138A (es) | Novedososo derivados de bencimidazol como antagonistas de ep4 | |
| CR20150370A (es) | Compuestos antivirales | |
| MX2019003738A (es) | Compuestos antivirales. | |
| UY35572A (es) | Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4) | |
| CU20140048A7 (es) | Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos | |
| CO6470845A2 (es) | Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales | |
| BR112012029647A2 (pt) | novos derivados de pirimidinas | |
| DOP2014000012A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
| CU24263B1 (es) | Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer | |
| MX346143B (es) | Ligandos del receptor ep1. | |
| MX2019003026A (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
| UY36228A (es) | Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen | |
| CL2018000856A1 (es) | Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida. | |
| CR20140257A (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 | |
| BR112014026817A2 (pt) | derivados do pantotenato para o tratamento de transtornos neurológicos | |
| GB2527958A (en) | Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents | |
| CU20130108A7 (es) | Novedosos derivados heterocíclicos |